WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/080393 International Application No.: PCT/SG2017/050517
Publication Date: 03.05.2018 International Filing Date: 16.10.2017
Chapter 2 Demand Filed: 06.04.2018
C12N 15/113 (2010.01) ,A61K 31/7088 (2006.01) ,A61P 35/00 (2006.01)
Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH[SG/SG]; 1 Fusionopolis Way, #20-10 Connexis Singapore 138632, SG
Inventors: SURANA, Uttam; SG
WEE, Keng Boon; SG
LIN, Jing; SG
LIM, Bing; SG
Agent: AMICA LAW LLC; 30 Raffles Place #14-01 Chevron House Singapore 048622, SG
Priority Data:
(EN) The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
(FR) La présente invention concerne des oligonucléotides antisens pour moduler l'activité de la glycine décarboxylase (GLDC). En particulier, la présente invention concerne des oligonucléotides antisens capables d'induire un saut d'exon d'ARN. L'invention concerne également des compositions pharmaceutiques, des kits et des méthodes de traitement du cancer et d'induction de saut d'exon à l'aide desdits oligonucléotides antisens. De plus, l'invention concerne une méthode d'aide à la catégorisation ou à la détermination du pronostic d'un cancer ou dans la sélection d'une stratégie thérapeutique pour un patient atteint d'un cancer, sur la base de l'évaluation du niveau d'acide nucléique, de protéine ou d'activité de la GLDC, dans un échantillon issu du patient.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)